News and Comments

Biomarin: The DMD Drug and the FDA Committee Options

  Tuesday, November 24, 2015

Today, the FDA advisory panel will discuss BioMarin (BMRN) product drisapersen for Duchenne muscular dystrophy based on documents released to the committee by the FDA. The FDA said, “The benefit of drisapersen in exon 51 skip amenable patients is inconclusive at this time. Therefore, the benefit-risk assessments were not made.”  More...

VERTEX: Orkambi Approved In Europe. What Vertex is Doing to Further improve CF Treatments

  Friday, November 20, 2015

Europe Approves Orkambi®  More...

Ziopharm Wages Its Own War On Brain Cancer

  Thursday, November 19, 2015

When we hear about a new approach that promises bringing in hopefulness in patients diagnosed with brain glioma, we try to listen and hope for the best, rather than develop and demonstrate  skepticism. Are we not walking the road of genetic engineering, gene therapy approaches and immunotherapy? Our optimism becomes realistic, especially when a scientific rationale is explained by researchers in scientifically solid firms that are specialized in cancer treatment with novel breakthrough methods.  More...

Aimmune Therapeutics: Oral Peanut desensitization Treatment is Promising

  Wednesday, November 11, 2015

Food allergies are bad, significant, dangerous and growing in the U.S. and the rest of the world. More than 30 million people in the United States and Europe have a food allergy, and more than five million people in the United States and Europe have peanut allergy, including more than two million children.  More...

Exelixis Will Begin Reaping the Fruits

  Tuesday, November 10, 2015

 More...

Incyte Is a Great Biotech Firm

  Saturday, November 07, 2015

To shareholders who were stupefied with an instigated selloff of Incyte’s (INCY) stock today, we say do not get panicky. Nothing is wrong with Incyte, no bad news was announced with any of the firm’s 12 ongoing clinical trials or with its approved drug Jakafi, which demonstrated progressive growth since it was launched.  So, a clever correct move now would be taking advantage and accumulate INCY.  More...

Dyax Acquisition and Biocryst Future

  Tuesday, November 03, 2015

 More...

Another Durable Botulinum Toxin with Many Advantages Over Botox

  Thursday, October 29, 2015

Another Durable, Botulinum Toxin with Many Advantages More...

Cytokinetics Heart Failure Drug Worked

  Tuesday, October 27, 2015

POSITIVE TOP-LINE RESULTS FROM A PHASE 2 TRIAL OF OMECAMTIV MECARBIL IN PATIENTS WITH CHRONIC HEART FAILURE More...

URGENT BREAKING NEWS

  Thursday, October 22, 2015

The FDA issued a warning that hepatitis C treatment Viekira Pak and Technivie can cause serious side effects and serious liver injury, mostly in patients with underlying advanced liver disease.  More...


Recent Postings


Archive


Tags

Spike Therapeutics (ONCE) Roche (RHHBY) Dendreon (DNDN) Prolor Biotech (PBTH) CompuGen (CGEN) Adaptimmune (ADAP) Aimmune Therapeutics (AIMT) Sanofi-Aventis (SAN) Illumina (ILMN) INNOVIVA (INVA) Prosensa (RNA) REGULUS (RGLS) Xoma (XOMA) Telaprevir Onyx (ONXX) ADVENTRIX (ANX) ABBVIE (ABBV) Vitae Pharmaceuticals (VTAE) Ariad (ARIA) Exelixis (EXEL) Roche (ROCHE) Theravance (THRX) GlaxoSmithKline (GSK) Mirati Therapeutics (MRTX) Alder Biopharmaceuticals (ALDR) Ridaforolimus Idenix (IDIX) NOVOCURE (NVCR) Zerenex PTC Therapeutics (PTCT) ARGOS (ARGS) PORTOLA (PTLA) Biogen Idec (BIIB) Bellicum (BLCM) OncoCyte (OCX) MODERNA Global Cell Therapeutics (GBT) Micromet (MITI) ACADIA (ACAD) galapagos (GLPG) Cytokinetics (CYTK) Sangamo (SGMO) Inovio (INO) RenenxBio (RGNX) Regeneron (REGN) Anadys (ANDS) JUNO (JUNO) Bristol-Myers Squibb (BMY) Intercept (ICPT) Jazz Pharmaceuticals (JAZZ) ZALTRAP™ NEKTAR (NKTR)) Sequenom (SQNM) HALOZYME (HALO) KITE (KITE) Sarepta (SRPT) Intrexon (XON) Theravance Bio Pharma (TBPH) Rapamune OSI (OSIP) C4 Therapeutics LEXICON (LXRX) CRISPR Therapeutics (CRSP) KERYX (KERX) Amgen (AMGN) Gilead (GILD) NANTKWEST (NK) Vertex (VRTX) AGOS (ARGS) NEUROCRINE (NBIX) Array Pharmaceuticals (ARRY) ISIS (ISIS) Velcade (bortezomib) Multiple Myeloma Human Genome Sciences (HGSI) VANDA (VNDA) Dynavax (DVAX) Merck (MRK) BIOMARIN (BMRN) SERES THERAPEUTICS (MCRB) GUARDIAN HEALTH Genentech Alnylam (ALNY) Benlysta (belimumab) Intermune (ITMN) CEMPRA (CEMP) Herceptin Sanofi (SNA) JOUNCE THERAPEUTICS (JNCE) Advaxis (ADXS) Auspex (ASPX) Agenus (AGEN Seattle Genetics (SGEN) Endometrial Cancer Agenus (AGEN) Trastuzumab-DM1 Human Longevity (HLI) TOKAI (TKAOI) ImmunoGen (IMGN) Elan (ELN) Editas (EDIT) SUNESIS PHARMACEUTICALS (SNSS) SYNTA (SNTA) Incyte (INCY) Galena (GALE) Abbott Laboratories (ABT) Pluristem (PSTI) Ocular Therapeutix (OCUL) Tysabri Valeant Pharmaceuticals International (VRX) Anacor (ANAC) AERIE PHARMACEUTICALS Revlimid (lenolidamide) ARCA (ABIO) Sanofi (SNY) Ionis (IONS) AstraZeneca (AZN) Ziofpharm (ZIOP) Biocryst (BCRX) IDERA (IDRA)